Clinical trial
Effect of a Structured Acupuncture Protocol on Symptom Burden, Quality of Life, and Neuropeptide Biomarkers in Patients With End-Stage Kidney Disease Undergoing Hemodialysis or Peritoneal Dialysis: A Prospective, Randomized, Blinded, Sham-Controlled Trial
NCT07887607 is registered in ClinicalTrials.gov with University General Hospital of Heraklion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of a Structured Acupuncture Protocol on Symptom Burden, Quality of Life, and Neuropeptide Biomarkers in Patients With End-Stage Kidney Disease Undergoing Hemodialysis or Peritoneal Dialysis: A Prospective, Randomized, Blinded, Sham-Controlled Trial
- Lead sponsor
- University General Hospital of Heraklion
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- September 30, 2029
- Enrollment
- 160 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
end stage kidney disease (eskd)
Arms
As registered; 2 arms.
-
Acupuncture
Participants will receive a structured acupuncture protocol in addition to usual care. Treatment will consist of 2-3 sessions per week for up to 24 sessions over 8-12 weeks. The protocol will include a standardized core set of acupuncture points, with limited individualized additional points based on clinical presentation and Traditional Chinese Medicine assessment. Body acupuncture and auricular acupuncture may be used. Acupuncture will be performed by trained members of the research team at the University General Hospital of Heraklion.
-
Sham Acupuncture
Participants will receive sham acupuncture in addition to usual care, with the same treatment frequency, session duration, and general procedural setting as the experimental group. Sham acupuncture will be performed at non-acupuncture points using superficial needle insertion (1-2 mm), without elicitation of deqi, needle manipulation, or electrical stimulation. No modification of usual care will be made as part of the sham intervention.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in health-related quality of life assessed by KDQOL-36 domain scores
Health-related quality of life will be assessed using the Kidney Disease Quality of Life 36-item questionnaire (KDQOL-36). The instrument includes the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS), as well as three kidney disease-specific domains: Symptoms and Problems, Effects of Kidney Disease, and Burden of Kidney Disease. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life. The KDQOL-36 will be administered at baseline, at week 6, at the end of the 12-week intervention, and at the 12-week post-intervention follow-up (24 weeks). Changes over time will be compared between the acupuncture and sham acupuncture groups.
Papers
PubMed papers this trial cites; 5 papers, results papers first, then newest first.
Lead sponsor's other trials
University General Hospital of Heraklion, most recent start first.
Similar trials
Same condition (Kidney Failure, Chronic) and phase, most recent start first.
+756 more trials See the condition page